

Rec'd PCT/PTO 31 JAN 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number  
**WO 2004/013134 A3**

(51) International Patent Classification<sup>7</sup>: **C07D 417/14**,  
A61K 31/425, A61P 13/12

(21) International Application Number:  
PCT/EP2003/008385

(22) International Filing Date: 29 July 2003 (29.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0217787.1 31 July 2002 (31.07.2002) GB

(71) Applicant (*for all designated States except US*):  
**SMITHKLINE BEECHAM CORPORATION**  
[US/US]; One Franklin Plaza, P O Box 7929, Philadelphia,  
PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DODIC, Ner-  
ina** [FR/FR]; Laboratoire GlaxoSmithKline, Centre de  
Recherches, Z A de Courtaboeuf, 25 avenue de Quebec,  
F-91940 Les Ulis (FR). **GELLIBERT, Francoise, Jeanne**  
[FR/FR]; GlaxoSmithKline, Centre de Recherches, Z A  
de Courtaboeuf, 25 avenue de Quebec, F-91940 Les Ulis  
(FR).

(74) Agent: **SEWELL, Richard, Charles**; GlaxoSmithKline,  
Corporate Intellectual Property CN925.1, 980 Great West  
Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments*

(88) Date of publication of the international search report:  
25 March 2004

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOUNDS

(57) Abstract: The invention relates to novel aminothiazole derivatives which are inhibitors of the transforming growth factor, ("TGF")- $\beta$  signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF- $\beta$  type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.

WO 2004/013134 A3